Literature DB >> 15978329

Stromal cell-derived factor-1 (SDF-1) alleles and susceptibility to breast carcinoma.

Mahboobeh Razmkhah1, Abdul-Rasoul Talei, Mehrnoosh Doroudchi, Tahereh Khalili-Azad, Abbas Ghaderi.   

Abstract

Stromal cell-Derived Factor-1 (SDF-1, CXCL12) is one the ELR- CXC angiogenic chemokines. It contributes to hematopoiesis and lymphocyte trafficking. SDF-1 and its exclusive receptor, CXCR4, are reported to play important roles in tumor growth, angiogenesis and metastasis of different types of tumors such as breast, lung, prostate and pancreatic cancers. SDF-1 gene polymorphism, known as SDF1-3'A, has been investigated in HIV-1 infection and the incidence of breast cancer. This investigation was aimed to study the frequency of SDF1-3'A mutation in Iranian women with breast cancer. Results showed that the frequency of AA and AG genotypes was higher among patients, while the frequency of GG genotype was lower compared to the controls. Thus AA and AG genotypes of SDF-1 may be considered as factors increasing the susceptibility of Iranian women to breast cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15978329     DOI: 10.1016/j.canlet.2004.10.039

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  29 in total

1.  The role of polymorphisms of genes CXCL12/CXCR4 and MIF in the risk development IBD the Polish population.

Authors:  Jerzy Mrowicki; Karolina Przybylowska-Sygut; Lukasz Dziki; Andrzej Sygut; Jan Chojnacki; Adam Dziki; Ireneusz Majsterek
Journal:  Mol Biol Rep       Date:  2014-04-01       Impact factor: 2.316

2.  Common sequence variants in chemokine-related genes and risk of breast cancer in post-menopausal women.

Authors:  Clara Bodelon; Katheleen E Malone; Lisa G Johnson; Mari Malkki; Effie W Petersdorf; Barbara McKnight; Margaret M Madeleine
Journal:  Int J Mol Epidemiol Genet       Date:  2013-11-28

3.  CXCL12 G801A polymorphism and breast cancer risk: a meta-analysis.

Authors:  Weisheng Shen; Xiangming Cao; Lei Xi; Lichun Deng
Journal:  Mol Biol Rep       Date:  2011-06-05       Impact factor: 2.316

4.  CXCL12 G801A polymorphism and cancer risk: An updated meta-analysis.

Authors:  Dan Meng; Yin-Xiang Wu; Vidhi Heerah; Shuang Peng; Meng-di Chu; Yong-Jian Xu; Wei-Ning Xiong; Shu-Yun Xu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-06-14

5.  Paracrine modulation of CXCR4 by IGF-1 and VEGF: implications for choroidal neovascularization.

Authors:  Nilanjana Sengupta; Aqeela Afzal; Sergio Caballero; Kyung-Hee Chang; Lynn C Shaw; Ji-Jing Pang; Vincent C Bond; Imran Bhutto; Takayuki Baba; Gerard A Lutty; Maria B Grant
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-12-10       Impact factor: 4.799

6.  SDF-1 and CCR5 genes polymorphism in patients with head and neck cancer.

Authors:  Bijan Khademi; Mahboobeh Razmkhah; Nasrollah Erfani; Marjan Gharagozloo; Abbas Ghaderi
Journal:  Pathol Oncol Res       Date:  2008-04-02       Impact factor: 3.201

7.  SDF-1alpha G801A polymorphism in Southern Iranian patients with colorectal and gastric cancers.

Authors:  Mahboobeh Razmkhah; Abbas Ghaderi
Journal:  Indian J Gastroenterol       Date:  2012-12-16

8.  SDF1-3' a gene polymorphism is associated with laryngeal cancer.

Authors:  Lukasz Kruszyna; Margarita Lianeri; Małgorzata Rydzanicz; Krzysztof Szyfter; Paweł P Jagodziński
Journal:  Pathol Oncol Res       Date:  2009-10-16       Impact factor: 3.201

9.  Genetic variation in CXCL12 and risk of cervical carcinoma: a population-based case-control study.

Authors:  S N Maley; S M Schwartz; L G Johnson; M Malkki; Q Du; J R Daling; S S Li; L P Zhao; E W Petersdorf; M M Madeleine
Journal:  Int J Immunogenet       Date:  2009-09-24       Impact factor: 1.466

10.  CXCL12 rs1801157 polymorphism in patients with breast cancer, Hodgkin's lymphoma, and non-Hodgkin's lymphoma.

Authors:  Karen Brajão de Oliveira; Julie Massayo Maeda Oda; Julio Cesar Voltarelli; Thiago Franco Nasser; Mario Augusto Ono; Thiago Cezar Fujita; Tiemi Matsuo; Maria Angelica Ehara Watanabe
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.